Creathor Manager Karlheinz Schmelig im Gespräch Sie investieren in Life Science- sowie in Technologieunternehmen. Warum gerade diese Verknüpfung? Life Sciences sowie auch der High Tech Markt zeigen von jeher ein…
Presenter name: Gilles Nobecourt, Partner Description: Gilles Nobecourt talks about EdRIP, its investment strategy and one current dominating trend. With about €600 million under management and currently raising its fifth…
Presenter name: Karl Nägler, Partner Description: Karl Nägler talks about Gimv, the investment strategy and current financing trends in the private life science sector. The dry period in 2000 to…
Auf dem Weg von der Idee bis zum Markteinzug eines neuen Therapeutikums muss man einige Hürden überwinden. Alleine die Durchführung klinischer Studien verschlingt hohe Geldsummen, die die Newcomer in der…
Four questions for Prof. Dr. Hartmut Ehrlich, CEO of ABIVAX S.A. What are the main reasons that you are attending BIO-Europe 2016? ABIVAX has established itself as an innovative biotechnology…
An Interview with Miguel Sieler, CEO of Neovacs Why are you attending the Bio-Europe 2016? BIO events are regular occasion where Biotech companies can meet up with the pharmaceutical industry…
Cell and gene therapy are the latest innovative approaches in the war against cancer and have the potential to revolutionize the pharmaceutical industry and save millions of lives. Conventional cancer…
An interview with Rémi Soula, co-Founder and Director of Business Development & Intellectual Property at Adocia, about his reasons for attending BIO-Europe, the pros & cons of running a family business and the…
We must rethink our healthcare system and the way we look at diseases. This is the main message from the expert panel that discussed „Ageing and health“ at the BIO-Europe…